Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysis

The Lancet Infectious Diseases

Volumn 10, Issue 6, 2010, Pages 387-394

  Horne, David J ^a   Royce, Sarah E ^c   Gooze, Lisa ^d   Narita, Masahiro ^a,b   Hopewell, Philip C ^c   Nahid, Payam ^c   Steingart, Karen R ^c  

^a Division of Pulmonary and Critical Care Medicine   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d San Mateo County Public Health Department   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; THIOACETAZONE;

BACTERIUM CULTURE; CLINICAL TRIAL; HUMAN; LUNG TUBERCULOSIS; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REGRESSION ANALYSIS; RELAPSE; REVIEW; SENSITIVITY AND SPECIFICITY; SPUTUM CULTURE; SPUTUM CYTODIAGNOSIS; SPUTUM EXAMINATION; SPUTUM SMEAR; SYSTEMATIC REVIEW; TREATMENT FAILURE;

BACTERIOLOGICAL TECHNIQUES; DRUG MONITORING; HUMANS; MICROSCOPY; MYCOBACTERIUM TUBERCULOSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECURRENCE; SENSITIVITY AND SPECIFICITY; SPUTUM; TREATMENT FAILURE; TUBERCULOSIS;

EID: 77952473253     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(10)70071-2     Document Type: Review

References (50)

1. WHO. Global tuberculosis control 2009: epidemiology, strategy, financing [WHO/HTM/TB/2009.411]. http://www.who.int/entity/tb/publications/global_report/2009/pdf/full_report.pdf (accessed March 29, 2010).
2. WHO. Treatment of tuberculosis guidelines (4th edn). http://www.who.int/tb/publications/tb_treatmentguidelines/en/index.html (accessed March 29, 2010).
3. Dye C., Watt C.J., Bleed D.M., Hosseini S.M., and Raviglione M.C. Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally. JAMA 293 (2005) 2767-2775
4. Sterling T.R., Alwood K., Gachuhi R., et al. Relapse rates after short-course (6-month) treatment of tuberculosis in HIV-infected and uninfected persons. AIDS 13 (1999) 1899-1904
5. Hong Kong Chest Service, and British Medical Research Council. Five-year follow-up of a controlled trial of five 6-month regimens of chemotherapy for pulmonary tuberculosis. Am Rev Respir Dis 136 (1987) 1339-1342
6. WHO Global Tuberculosis Programme. Treatment of tuberculosis: guidelines for national programmes (3rd edn) [WHO/CDS/TB/2003.313]. http://whqlibdoc.who.int/HQ/2003/WHO_CDS_TB_2003.313_eng.pdf (accessed March 29, 2010).
7. Wilkinson D., Bechan S., Connolly C., Standing E., and Short G.M. Should we take a history of prior treatment, and check sputum status at 2-3 months when treating patients for tuberculosis?. Int J Tuberc Lung Dis 2 (1998) 52-55
8. Enarson D.A., Jindani A., Kuaban C., et al. Appropriateness of extending the intensive phase of treatment based on smear results. Int J Tuberc Lung Dis 8 (2004) 114-116
9. Benator D., Bhattacharya M., Bozeman L., et al. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet 360 (2002) 528-534
10. Jindani A., Nunn A.J., and Enarson D.A. Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial. Lancet 364 (2004) 1244-1251
11. Mitchison D.A. Shortening the treatment of tuberculosis. Nat Biotechnol 23 (2005) 187-188
12. Zhao F.Z., Levy M.H., and Wen S. Sputum microscopy results at two and three months predict outcome of tuberculosis treatment. Int J Tuberc Lung Dis 1 (1997) 570-572
13. Wallis R.S., Doherty T.M., Onyebujoh P., et al. Biomarkers for tuberculosis disease activity, cure, and relapse. Lancet Infect Dis 9 (2009) 162-172
14. Deville W.L., Buntinx F., Bouter L.M., et al. Conducting systematic reviews of diagnostic studies: didactic guidelines. BMC Med Res Methodol 2 (2002) 9
15. Gatsonis C., and Paliwal P. Meta-analysis of diagnostic and screening test accuracy evaluations: methodologic primer. AJR Am J Roentgenol 187 (2006) 271-281
16. Pai M., McCulloch M., Enanoria W., and Colford Jr. J.M. Systematic reviews of diagnostic test evaluations: what's behind the scenes?. ACP J Club 141 (2004) A11-A13
17. Leeflang M.M., Deeks J.J., Gatsonis C., and Bossuyt P.M. Systematic reviews of diagnostic test accuracy. Ann Intern Med 149 (2008) 889-897
18. Rom W.N., and Garay S.M. Tuberculosis. 2nd edn. (2004), Lippincott Williams & Wilkins, Philadelphia
19. Shingadia D., and Novelli V. Diagnosis and treatment of tuberculosis in children. Lancet Infect Dis 3 (2003) 624-632
20. Cao J.P., Zhang L.Y., Zhu J.Q., and Chin D.P. Two-year follow-up of directly-observed intermittent regimens for smear-positive pulmonary tuberculosis in China. Int J Tuberc Lung Dis 2 (1998) 360-364
21. Whiting P., Rutjes A.W., Reitsma J.B., Bossuyt P.M., and Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 3 (2003) 25
22. Guyatt G.H., Oxman A.D., Vist G.E., et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336 (2008) 924-926
23. Rutter C.M., and Gatsonis C.A. A hierarchical regression approach to meta-analysis of diagnostic test accuracy evaluations. Stat Med 20 (2001) 2865-2884
24. Ling D.I., Flores L.L., Riley L.W., and Pai M. Commercial nucleic-acid amplification tests for diagnosis of pulmonary tuberculosis in respiratory specimens: meta-analysis and meta-regression. PLoS One 3 (2008) e1536
25. Harbord R., and Whiting P. Metandi: meta-analysis of diagnostic accuracy using hierarchical logistic regression. In: Sterne J. (Ed). Meta-analysis in Stata (2009), StataCorp LP, College Station, TX
26. Zamora J., Abraira V., Muriel A., Khan K., and Coomarasamy A. Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol 6 (2006) 31
27. Lijmer J.G., Bossuyt P.M., and Heisterkamp S.H. Exploring sources of heterogeneity in systematic reviews of diagnostic tests. Stat Med 21 (2002) 1525-1537
28. Chang K.C., Leung C.C., Yew W.W., Ho S.C., and Tam C.M. A nested case-control study on treatment-related risk factors for early relapse of tuberculosis. Am J Respir Crit Care Med 170 (2004) 1124-1130
29. Nettles R.E., Mazo D., Alwood K., et al. Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin use. Clin Infect Dis 38 (2004) 731-736
30. Picon P.D., Bassanesi S.L., Caramori M.L., Ferreira R.L., Jarczewski C.A., and Vieira P.R. Risk factors for recurrence of tuberculosis. J Bras Pneumol 33 (2007) 572-578
31. Tam C.M., Chan S.L., Kam K.M., Goodall R.L., and Mitchison D.A. Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Final report at 5 years: prognostic value of various measures. Int J Tuberc Lung Dis 6 (2002) 3-10
32. Thomas A., Gopi P.G., Santha T., et al. Predictors of relapse among pulmonary tuberculosis patients treated in a DOTS programme in South India. Int J Tuberc Lung Dis 9 (2005) 556-561
33. Ramarokoto H., Randriamiharisoa H., Rakotoarisaonina A., et al. Bacteriological follow-up of tuberculosis treatment: a comparative study of smear microscopy and culture results at the second month of treatment. Int J Tuberc Lung Dis 6 (2002) 909-912
34. Van Deun A., Aung K.J., Salim M.H., et al. Extension of the intensive phase reduces unfavourable outcomes with the 8-month thioacetazone regimen. Int J Tuberc Lung Dis 10 (2006) 1255-1261
35. Dembele S.M., Ouedraogo H.Z., Combary A., Saleri N., Macq J., and Dujardin B. Conversion rate at two-month follow-up of smear-positive tuberculosis patients in Burkina Faso. Int J Tuberc Lung Dis 11 (2007) 1339-1344
36. Rieder H.L. Sputum smear conversion during directly observed treatment for tuberculosis. Tuber Lung Dis 77 (1996) 124-129
37. Santha T., Garg R., Frieden T.R., et al. Risk factors associated with default, failure and death among tuberculosis patients treated in a DOTS programme in Tiruvallur District, South India, 2000. Int J Tuberc Lung Dis 6 (2002) 780-788
38. Zierski M., Bek E., Long M.W., and Snider Jr. D.E. Short-course (6 month) cooperative tuberculosis study in Poland: results 18 months after completion of treatment. Am Rev Respir Dis 122 (1980) 879-889
39. Koepsell T.D., and Weiss N.S. Epidemiologic methods: studying the occurrence of illness (2003), Oxford University Press, Oxford
40. Moskowitz C.S., and Pepe M.S. Comparing the predictive values of diagnostic tests: sample size and analysis for paired study designs. Clin Trials 3 (2006) 272-279
41. Pepe M.S., Janes H., Longton G., Leisenring W., and Newcomb P. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol 159 (2004) 882-890
42. Verver S., Warren R.M., Beyers N., et al. Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis. Am J Respir Crit Care Med 171 (2005) 1430-1435
43. Tatsioni A., Zarin D.A., Aronson N., et al. Challenges in systematic reviews of diagnostic technologies. Ann Intern Med 142 (2005) 1048-1055
44. Riley R.D., Sauerbrei W., and Altman D.G. Prognostic markers in cancer: the evolution of evidence from single studies to meta-analysis, and beyond. Br J Cancer 100 (2009) 1219-1229
45. Boshoff H.I., and Barry III C.E. Tuberculosis-metabolism and respiration in the absence of growth. Nat Rev Microbiol 3 (2005) 70-80
46. Johnson J.L., Hadad D.J., Dietze R., et al. Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion. Am J Respir Crit Care Med 180 (2009) 558-563
47. Mitchison D.A. Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months. Am Rev Respir Dis 147 (1993) 1062-1063
48. Perrin F.M., Lipman M.C., McHugh T.D., and Gillespie S.H. Biomarkers of treatment response in clinical trials of novel antituberculosis agents. Lancet Infect Dis 7 (2007) 481-490
49. Pepe M.S., Feng Z., Janes H., Bossuyt P.M., and Potter J.D. Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J Natl Cancer Inst 100 (2008) 1432-1438
50. Schunemann H.J., Oxman A.D., Brozek J., et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ 336 (2008) 1106-1110